{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-047856","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.038273+00:00","generated_at":"2026-05-21T13:56:09.625550+00:00","sec_items":["2.02","4.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tvardi completes merger with Cara, switches auditor to Deloitte, cash into 2H 2026","bullets":["Completed merger with Cara Therapeutics; received ~$23.8M net cash; cash runway expected into 2H 2026.","Dismissed Ernst & Young as auditor; engaged Deloitte & Touche for FY 2025; no disagreements reported.","Phase 2 data for TTI-101 in IPF expected 2H 2025; IND for TTI-109 planned 1H 2025.","Phase 1 study of TTI-101 in advanced solid tumors published in Clinical Cancer Research."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-047856","json":"https://secwatch.observer/filing/0001104659-25-047856.json","markdown":"https://secwatch.observer/filing/0001104659-25-047856.md","text":"https://secwatch.observer/filing/0001104659-25-047856.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465925047856/0001104659-25-047856-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465925047856/tm2514879d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T13:56:09.625550+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}